Citation:Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP 2004

From Cancer Guidelines Wiki

Citation


Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004 Jul 28;292(4):470-84 Available from: http://www.ncbi.nlm.nih.gov/pubmed/15280345.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP 2004What is the optimal systemic therapy for stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP 2004 2Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP 2004 3Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP 2004 4Are three chemotherapy agents better than two chemotherapy agents for treatment of stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP 2004 5What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:What is the optimal systemic therapy for stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal systemic therapy for stage IV inoperable NSCLC?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:Are three chemotherapy agents better than two chemotherapy agents for treatment of stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Are three chemotherapy agents better than two chemotherapy agents for treatment of stage IV inoperable NSCLC?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?
  2. What is the optimal systemic therapy for stage IV inoperable NSCLC?
Retrieved from "https://wiki.cancer.org.au/australiawiki/index.php?title=Citation:Delbaldo_C,_Michiels_S,_Syz_N,_Soria_JC,_Le_Chevalier_T,_Pignon_JP_2004&oldid=21619"